OX40 (ACT35) Mouse mAb #98785
- WB
- IP
- IHC
- IF
- F
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 35-50 |
| Source/Isotype | Mouse IgG2a |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IHC-Immunohistochemistry
- IF-Immunofluorescence
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| IHC Leica Bond | 1:400 |
| Immunohistochemistry (Paraffin) | 1:400 |
| Immunofluorescence (Immunocytochemistry) | 1:1000 |
| Flow Cytometry (Fixed/Permeabilized) | 1:200 |
| Flow Cytometry (Live) | 1:200 |
Storage
For a carrier free (BSA and azide free) version of this product see product #99419.
Protocol
Specificity / Sensitivity
OX40 (ACT35) Mouse mAb recognizes endogenous levels of total OX40 protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with HuT 102 cell line.
Background
OX40 (TNFRSF4, CD134) is a member of the tumor necrosis factor (TNF) receptor superfamily that regulates T cell activity and immune responses. The OX40 protein contains four cysteine rich domains, a transmembrane domain, and a cytoplasmic tail containing a QEE motif (1,2). OX40 is primarily expressed on activated CD4+ and CD8+ T-cells, while the OX40 ligand (OX40L, TNFSF4, CD252) is predominantly expressed on activated antigen presenting cells (3-7). The engagement of OX40 with OX40L leads to the recruitment of TNF receptor-associated factors (TRAFs) and results in the formation of a TCR-independent signaling complex. One component of this complex, PKCθ, activates the NF-κB pathway (2,8). OX40 signaling through Akt can also enhance TCR signaling directly (9). Research studies indicate that the OX40L-OX40 pathway is associated with inflammation and autoimmune diseases (10). Additional research studies show that OX40 agonists augment anti-tumor immunity in several cancer types (11,12).
- Croft, M. (2010) Annu Rev Immunol 28, 57-78.
- So, T. and Croft, M. (2012) Front Immunol 3, 133.
- Paterson, D.J. et al. (1987) Mol Immunol 24, 1281-90.
- Mallett, S. et al. (1990) EMBO J 9, 1063-8.
- Dürkop, H. et al. (1995) Br J Haematol 91, 927-31.
- Godfrey, W.R. et al. (1994) J Exp Med 180, 757-62.
- Al-Shamkhani, A. et al. (1997) J Biol Chem 272, 5275-82.
- So, T. et al. (2011) Proc Natl Acad Sci U S A 108, 2903-8.
- So, T. and Croft, M. (2013) Front Immunol 4, 139.
- Gough, M.J. and Weinberg, A.D. (2009) Adv Exp Med Biol 647, 94-107.
- Weinberg, A.D. et al. (2011) Immunol Rev 244, 218-31.
- Linch, S.N. et al. (2015) Front Oncol 5, 34.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.